Matthew R. Henn
President and Chief Scientific Officer · Seres Therapeutics, Inc.
- 2024
- Aug 18, 2026
- 10
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Matthew R. Henn files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Teresa L. Young - $19K in MCRB purchases and sales in the last 12 months
- Eric D. Shaff - $9K in MCRB purchases and sales in the last 12 months
- Thomas Desrosier - $3K in MCRB purchases and sales in the last 12 months
- Kelly Brady - $735 in MCRB purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Matthew R. Henn?
Matthew R. Henn is a corporate insider, tracked as President and Chief Scientific Officer of Seres Therapeutics, Inc. (MCRB). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Matthew R. Henn submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Matthew R. Henn been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($28K) across all tracked filings.
